Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CRNX News 29 September 2025 - 7 January 2026

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved acromegaly drug. Crinetics said it generated preliminary, unaudited net product revenue of more than $5 million from PALSONIFY in the fourth quarter of 2025, with more than 200 enrollment forms and over 125 unique prescribers by the end of December. It also posted Phase 2 results for atumelnant in congenital adrenal hyperplasia (CAH), reporting a 67% mean reduction in androstenedione
7 January 2026
·····
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025)

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) stock slid sharply on Thursday, December 18, 2025, after a regulatory filing revealed a leadership transition involving the company’s Chief Medical and Development Officer. In trading, CRNX fell roughly 8% to around the mid‑$40s, with the day’s range stretching from the low‑$40s to the high‑$40s as investors digested the update. Investing.com For a biotech stock—especially one in the middle of a major product launch and multiple late‑stage trials—management continuity matters. But so do fundamentals: Crinetics is no longer “just” a clinical-stage story. It recently reached a pivotal milestone with its first FDA-approved product, and its
18 December 2025
·····
Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Massive Moves: Record Deals, FDA Wins & Crypto Mania Propel Top Stock Gainers (Sep 29, 2025)

Wall Street’s Winning Streak and Market Backdrop Even as a possible U.S. government shutdown loomed on Capitol Hill, Wall Street managed a modest rise on September 29, 2025. The tech-heavy Nasdaq Composite climbed about 0.5% on the day reuters.com, with investors largely shrugging off fiscal uncertainty. “Investors are clinging to the positives,” noted one strategist, citing hopes of future interest rate cuts and solid economic data reuters.com. Against this cautiously optimistic backdrop, a handful of individual stocks delivered outsized gains thanks to company-specific catalysts – from blockbuster M&A deals to drug approvals and speculative frenzies. Below, we break down the
29 September 2025
········

Stock Market Today

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop